Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
214
datasets available to search
ShareScore release 0.9.0
Dataset results
214 results for “Denosumab”
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
ClinicalTrials.gov study NCT07085520. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Denosumab in Healthy Adults
ClinicalTrials.gov study NCT03427853. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative
ClinicalTrials.gov study NCT07034391. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Denosumab for Type 1 Diabetes
ClinicalTrials.gov study NCT06524960. IPD Sharing: Not stated. Countries: 1. Publications: 0.
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
ClinicalTrials.gov study NCT06767150. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
ClinicalTrials.gov study NCT00887965. IPD Sharing: Not stated. Countries: 0. Publications: 0.
RANKL regulates testicular cancer growth and Denosumab has tumor suppressive effects in GCNIS and advanced seminoma
GEO Series GSE197389. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Denosumab Enhances antitumour Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells
GEO Series GSE268835. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.
ClinicalTrials.gov study NCT04231682. IPD Sharing: NO. Countries: 0. Publications: 0.
Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
ClinicalTrials.gov study NCT05559268. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark
ClinicalTrials.gov study NCT02066805. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study Evaluating Denosumab on Vascular and Bone Metabolism in Osteoporotic Chronic Kidney Disease (HDENOBS)
ClinicalTrials.gov study NCT05234047. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dataset related to article "Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors "
<p>This record contains raw data related to article "Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors"</p><p>Abstract</p><p><strong>Purpose: </strong>Trabecular bone score (TBS) is a gray-level textural metric that has shown to correlate with risk of fractures in several forms of osteoporosis. The value of TBS in predicting fractures and the effects of bone-active drugs on TBS in aromatase inhibitors (AIs)-induced osteoporosis are still largely unknown. The primary objective of this retrospective study was to assess the effects of denosumab and bisphosphonates (BPs) on TBS and vertebral fractures (VFs) in women exposed to AIs.</p><p><strong>Methods: </strong>241 consecutive women (median age 58 years) with early breast cancer undergoing treatment with AIs were evaluated for TBS, bone mineral density (BMD) and morphometric VFs at baseline and after 18-24 months of follow-up. During the study period, 139 women (57.7%) received denosumab 60 mg every 6 months, 53 (22.0%) BPs, whereas 49 women (20.3%) were not treated with bone-active drugs.</p><p><strong>Results: </strong>Denosumab significantly increased TBS values (from 1.270 to 1.323; P < 0.001) accompanied by a significant decrease in risk of VFs (odds ratio 0.282; P = 0.021). During treatment with BPs, TBS did not significantly change (P = 0.849) and incidence of VFs was not significantly different from women untreated with bone-active drugs (P = 0.427). In the whole population, women with incident VFs showed higher decrease in TBS vs. non-fractured women (P = 0.003), without significant differences in changes of BMD at any skeletal site.</p><p><strong>Conclusions: </strong>TBS variation predicts fracture risk in AIs treated women. Denosumab is effective to induce early increase of TBS and reduction in risk of VFs</p>
Dataset related to article "Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors "
<p>This record contains raw data related to article “Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors"</p> <p>Abstract</p> <p>Bone-active drugs are recommended to protect the skeleton from detrimental actions of aromatase inhibitors (AIs). However, most of literature data are focused on bone mineral density (BMD), whereas data on fractures are scant. The aim of this prospective study was to investigate the real-life effectiveness of denosumab, oral bisphosphonates (BPs) and intravenous zoledronate on risk of vertebral fractures (VFs) induced by AIs. 567 consecutive women (median age 62 years, range 28-83) with early breast cancer undergoing treatment with AIs were evaluated for morphometric VFs and BMD at baseline and after 18-24 months of follow-up. After enrollment, 268 women (47.3%) started denosumab 60 mg subcutaneously every 6 months, 115 (20.3%) BPs (59 with oral BPs and, 56 with intravenous zoledronate 5 mg/12 months), whereas 184 women (32.5%) were not treated with bone-active drugs for several reasons. During follow-up, 54 women (9.5%) developed incident VFs in association with age of subjects (P < 0.001), baseline FRAX scores for major fractures (P < 0.001) and hip fractures (P = 0.003), pre-existing VFs (P < 0.001), change in BMD at lumbar spine (P = 0.015), femoral neck (P = 0.003) and total hip (P < 0.001). Risk of VFs was higher in subjects who were untreated as compared to those treated with bone-active drugs (32/184 vs. 22/383; P < 0.001). Specifically, fracture risk was significantly decreased by denosumab [odds ratio (OR) 0.22; P < 0.001] and zoledronate (OR 0.27; P = 0.035), but not by oral BPs (P = 0.317). These data suggest that in real-world clinical practice, denosumab and zoledronate can reduce AI-related risk of VFs after only 24 months of treatment.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.